2014
DOI: 10.1038/leu.2014.227
|View full text |Cite
|
Sign up to set email alerts
|

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

Abstract: Oral melphalan and dexamethasone (MDex) is a standard treatment for patients with AL amyloidosis who are not eligible for stem cell transplantation at many referral centers. However, following encouraging reports on the activity of bortezomib combined with alkylators and dexamethasone, these combinations are being moved to frontline therapy. We compared the outcome of 87 patients treated with bortezomib plus MDex (BMDex) with that of 87 controls treated with MDex. Patients and controls were matched for age, ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

3
90
1
4

Year Published

2014
2014
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 120 publications
(98 citation statements)
references
References 44 publications
3
90
1
4
Order By: Relevance
“…A case-control study did not find a difference in the death rate at 6 months between MDex and bortezomib in combination with MDex. 8 Cardiac toxicity in bortezomib-treated patients exists.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A case-control study did not find a difference in the death rate at 6 months between MDex and bortezomib in combination with MDex. 8 Cardiac toxicity in bortezomib-treated patients exists.…”
Section: Discussionmentioning
confidence: 99%
“…5 For patients ineligible for ASCT, melphalan in combination with dexamethasone (MDex) showed effective results. 6 Bortezomib added to the alkylator/ corticosteroid backbone has increased the rate of deep hematological responses, 7,8 and bortezomib-based regimens are the most used induction regimens. Immunomodulatory drugs (IMiDs) have been less effective and less well tolerated in AL patients compared with myeloma, [9][10][11] but remain an effective treatment option for some patients.…”
Section: Introductionmentioning
confidence: 99%
“…The therapeutic options have now been increased by the establishment of the melphalan-dexamethasone protocol, 5 by the introduction of proteasome inhibitors such as bortezomib 6,7 and immunomodulatory drugs such as lenalidomide, 8,9 and by their use in combination therapies. [10][11][12][13] However, HDM offers the prospect of long-term remission in AL. [14][15][16] Therefore, it remains a therapeutic option for carefully selected AL patients at specialized centers, 15 although controversy regarding its pros and cons persists.…”
Section: Introductionmentioning
confidence: 99%
“…10,23 However, these studies have compared bortezomib-with non-bortezomibcontaining regimens. The prospective study comparing BMDex with MDex also compares a bortezomib-containing with a nonbortezomib-containing regimen; thus, our study is quite different in this respect.…”
Section: Discussionmentioning
confidence: 99%